Mitral stenosis accounts for roughly twelve percent of patients with disease confined to a single heart valve, and it comes in two very different flavors. Rheumatic mitral stenosis, long the dominant form worldwide, arises from repeated group A streptococcal infections. Molecular mimicry between bacterial antigens and valve proteins triggers an autoimmune attack that fibroses the leaflets and fuses their commissures, sculpting the valve into a funnel whose tightest point sits at the leaflet tips. Mitral annular calcification, by contrast, is an inflammatory disease of aging in which calcium deposits build up in the fibrous ring anchoring the valve, sometimes extending onto the leaflet bases and forming a rigid calcific tunnel. In this condition the narrowest flow channel lies near the annulus rather than at the tips, and the entire valve apparatus takes on a shrunken appearance. In a large United States echocardiographic cohort, annular calcification was found in twenty-three percent of imaged patients, and stenosis was present in 6.6 percent of those with calcification compared with just 0.5 percent of those without. Prognosis is sobering: five-year survival in mitral stenosis associated with annular calcification has been reported below fifty percent.

Clinical imaging struggles to distinguish what these two diseases actually do to the blood. Doppler echocardiography measures velocities only along the ultrasound beam, so it cannot reconstruct the full three-dimensional velocity field inside the ventricle, and even four-dimensional flow magnetic resonance imaging lacks the resolution to capture the fine shear layers where viscous energy is dissipated. Earlier laboratory work using planar particle image velocimetry had hinted that calcific stenosis dissipates more energy than the rheumatic form, but a single imaging plane can miss out-of-plane velocities entirely. Because ventricular flow is inherently three-dimensional, the team turned to high-fidelity computation to see what planar measurements might be hiding.

The researchers built their virtual laboratory around real patients. Three mitral valve geometries, one healthy, one rheumatic, and one calcific, were digitally extracted from four-dimensional echocardiography at the moment of systolic closure, thickened to one millimeter, and embedded in a left ventricle model derived from a silicone phantom used in prior bench experiments. The calcific case included an additional rigid ring representing the annular calcium. Using an immersed finite element-finite difference fluid-structure interaction scheme with adaptive mesh refinement, the team simulated eight consecutive cardiac cycles at seventy beats per minute across cardiac outputs of 1.5, 3.0, 3.5, and 5.0 liters per minute, discarding the first three cycles so that statistics were drawn from a periodic steady state. Blood was modeled as an incompressible Newtonian fluid with a viscosity of 4.0 millipascal-seconds, and parallel simulations with water-like viscosity allowed direct comparison with the original in vitro platform.

The classic diagnostic numbers told a familiar but incomplete story. Both diseased valves produced elevated transmitral pressure gradients relative to the healthy valve, as expected. The rheumatic valve had the smallest geometric and effective orifice areas, yet the differences in mean pressure gradient and peak velocity between the two diseases flipped depending on cardiac output: peak velocity was higher in the rheumatic case at reduced flows, but the calcific valve took the lead at the physiologic 5.0 liters per minute. When the gradients were scaled by orifice area, however, the calcific valve carried the heavier effective hemodynamic burden, consistent with earlier bench findings.

The energetics told a sharper tale. Despite the rheumatic valve’s tighter orifice and higher velocities, the calcific case demanded the greatest pump stroke work, the mechanical energy the ventricle must expend to sustain each beat, and it also produced the highest three-dimensional ventricular kinetic energy and viscous energy dissipation across all equivalent flow conditions. The healthy valve sat lowest on every energetic measure. Crucially, the gap between the two diseases widened dramatically when the full three-dimensional velocity field was used instead of a single plane. At 3.5 liters per minute with blood-analog viscosity, planar measurements suggested only a twenty percent difference in total cycle dissipation between the calcific and rheumatic cases; the three-dimensional analysis put it at fifty-one percent. The discrepancy traces to large out-of-plane velocities in the calcific case that a planar laser sheet simply cannot see, a finding with direct implications for how laboratory flow studies of diseased hearts should be designed and interpreted.

Flow visualization and particle tracking revealed why the energy bills differ. In the healthy configuration, streamlines curled gracefully around the leaflets, forming the classic diastolic vortex ring that funnels blood toward the outflow tract. Both diseased valves destroyed this structure, but in characteristically different ways. The calcific jet drove straight toward the ventricular apex, scattering particles into the lower half of the chamber, while the rheumatic jet slammed into the inferolateral wall and sent particles crawling along the wall toward the apex, away from the exit. Of two thousand massless particles released upstream of the valve, seven hundred eight were ejected from the ventricle within three cycles in the healthy blood-analog simulation at 3.5 liters per minute, compared with 396 for the calcific valve and a mere 107 for the rheumatic valve, none of which had left the chamber by the third cycle in the water simulations. Retained particles in the calcific case traveled the longest total distances, a signature of inefficient recirculation, while ejected particles in the rheumatic case lingered longest inside the ventricle, indicating delayed filling and impaired mixing.

The clinical stakes are considerable. Breathlessness and exercise intolerance define valvular disease, and in rheumatic stenosis intervention is generally recommended once the orifice area falls below 1.5 square centimeters. Calcific stenosis is murkier: patients are older, carry more comorbidities, and it is often unclear whether their symptoms stem from the valve itself or from the stiff atrial and ventricular compliance that typically accompanies annular calcification. Intervention in this population is technically harder and riskier. If the valve’s geometric distortion is a primary driver of the physiological derangement, as these simulations suggest, then valve intervention may be justified even when conventional pressure gradients look unremarkable. Conversely, if chamber stiffness dominates, replacement could incur more risk than benefit. Etiology-specific hemodynamic signatures of the kind uncovered here could help clinicians make that distinction.

The authors are careful to frame the work as a proof of concept with real limitations. Each disease was represented by a single anonymized valve, so inter-patient variability remains unexplored; the leaflets were modeled as isotropic silicone, the calcification as fully rigid, and the subvalvular apparatus of chordae and papillary muscles was absent, which also limited loading conditions and caused the healthy valve model to invert at the highest flow rate. The ventricle was larger than physiological, yielding a reduced ejection fraction, and no direct volumetric validation against experiment or clinic was performed. Some quantitative discrepancies with the underlying bench study, including valve velocities and effective orifice areas, likely reflect unavailable pressure measurements used to set boundary conditions. Still, the qualitative vortex disruption and the comparative energetic rankings reproduced the in vitro observations, and extending them to three dimensions exposed differences no planar measurement could capture. The team calls for studies with larger valve cohorts, more physiological material models, and complementary validation data. If those confirm the pattern, the humble vortex, invisible to the stethoscope and only partially visible to the echocardiographer, may become a genuine target in the care of an aging population increasingly affected by calcified heart valves.

Subject of Research: Patient-specific fluid-structure interaction analysis of ventricular vortex formation and flow energetics in rheumatic versus calcific mitral stenosis

Article Title: Patient-Specific Analysis of Ventricular Vortex Formation and Flow Energetics in Rheumatic and Calcific Mitral Stenosis

Article References: Davey, M., Hashemi, M. S., Pressman, G. S., Kheradvar, A., & Griffith, B. E. (2026). Patient-Specific Analysis of Ventricular Vortex Formation and Flow Energetics in Rheumatic and Calcific Mitral Stenosis. Annals of Biomedical Engineering. https://doi.org/10.1007/s10439-026-04364-7

Image Credits: AI Generated

DOI: 10.1007/s10439-026-04364-7

Keywords: mitral stenosis, mitral annular calcification, rheumatic heart disease, fluid-structure interaction, ventricular vortex, cardiac fluid dynamics, flow energetics, viscous energy dissipation, echocardiography, left ventricle, biomedical engineering, computational modeling

The research, led by Jafesi Pulle of the Rheumatic Heart Disease Research Collaborative in Uganda and the Uganda Heart Institute, together with colleagues at Makerere University, the University of Washington, the University of Cincinnati and Cincinnati Children’s Hospital Medical Center, was embedded within the ADUNU program, short for Accelerating Delivery of Rheumatic Heart Disease Preventive Services in Uganda. Rather than measuring adherence with pill counts or clinic logs, the team wanted to understand the lived experience of retention: what patients, caregivers, community leaders and healthcare providers themselves believe keeps people engaged with a preventive therapy that must continue for years, often for a decade or more, without interruption.

Methodologically, the study combined three focus group discussions with purposively selected patients, caregivers, community leaders and healthcare providers, alongside fifteen in-depth interviews with patients receiving care and, in two cases, their caregivers, of which fourteen interviews were included in the final analysis. The researchers deliberately sampled for variation in sex, age, adherence to prophylaxis and geographic location, so that the picture emerging from the transcripts would not simply reflect the most accessible or most compliant patients. Three independent coders then applied thematic content analysis, using a hybrid of inductive and deductive coding informed by two established frameworks: the Integrated Behavioral Model, which explains health behavior through intention, perceived norms and self-efficacy, and the Consolidated Framework for Implementation Research, which maps how interventions interact with the health systems that deliver them.

What emerged was not a single barrier or a single motivator but a layered account of retention as a dynamic, multilevel process. At the individual level, the strongest driver was a patient’s perceived necessity of the injections. When people understood that the penicillin was protecting their heart valves from further damage, motivation to attend was robust. But that understanding was fragile. Emotional responses to the diagnosis, particularly fear and uncertainty among newly diagnosed patients, could either galvanize engagement or push people toward denial. And the physical experience of the injection itself mattered enormously: the pain of intramuscular benzathine penicillin, delivered deep into the muscle with a wide-bore needle, was a recurring theme, and how patients were prepared for and supported through that pain shaped whether they came back the following month.

Around the individual sat a web of interpersonal supports that the authors found to be decisive. Caregivers, usually parents or older relatives, did much of the practical work of retention, from remembering appointment dates to arranging transport. Peer encouragement among patients normalized the routine and reduced the sense of being singled out by illness. Perhaps most striking was the role of distributed reminder systems, in which the responsibility for remembering an appointment was spread across family members, neighbors and community health workers rather than resting on the patient alone. In practice, this turned attendance into a shared social obligation, a form of distributed accountability that buffered against the forgetfulness, fatigue and competing demands that erode adherence in any long-term therapy.

Trust in healthcare providers emerged as another central pillar. Patients and caregivers who felt known, respected and well informed by the nurses and clinicians delivering the injections reported far greater confidence in the treatment itself. That confidence mattered because the benefits of secondary prophylaxis are abstract: a child who feels healthy has to trust that a monthly injection is preventing damage she cannot see or feel. Conversely, where communication was thin or staff turnover disrupted continuity, confidence wavered. The study also documented a darker social force: stigma. In communities where knowledge about rheumatic heart disease was limited, patients sometimes concealed their diagnosis or their clinic visits to avoid being labeled, and this concealment directly undermined engagement with care.

At the level of the health system, the researchers identified four features that shaped whether patients believed the decentralized program was worth trusting with their future. The first was the reliable availability of benzathine penicillin itself; stockouts, even occasional ones, sent a signal that the system could not guarantee the continuity on which the entire strategy depends. The second was workforce stability, because patients built relationships with specific providers and lost confidence when those providers disappeared. The third was the capacity of staff to deliver patient education, turning each clinic visit into an opportunity to reinforce why the injections matter. The fourth was continuity of service at decentralized sites close to patients’ homes, which removed the crushing transport costs and lost income associated with traveling to distant referral hospitals.

The significance of these findings extends well beyond northern Uganda. Rheumatic heart disease remains one of the most common forms of heart disease among children and young adults in low- and middle-income countries, and the World Health Assembly has called for global action to reduce deaths from the condition. Secondary prophylaxis is the cornerstone of that response, yet programs worldwide struggle with exactly the problem this study dissects: the therapy only works if it is delivered without interruption, for years, to populations facing poverty, long distances and limited health infrastructure. By showing that retention is produced through the interaction of individual perception, relational trust, social support and system reliability, the study reframes adherence as a property of the whole care ecosystem rather than a personal virtue of the patient.

The authors translate this insight into concrete programmatic recommendations. Strengthening counseling at diagnosis and at every subsequent visit could stabilize patients’ perceived necessity of treatment and soften the emotional shock of a lifelong diagnosis. Expanding community-based reminder mechanisms, building on Uganda’s Village Health Team network, would formalize the distributed reminder systems that patients and caregivers already improvise. Addressing stigma requires community education that demystifies rheumatic heart disease, so that a clinic visit becomes unremarkable rather than something to hide. And stabilizing the workforce, through training, supervision and retention incentives, protects the provider relationships on which patient confidence rests. None of these interventions is technologically novel; their power lies in being aimed at the actual determinants of retention rather than at assumptions about noncompliance.

There are limits worth noting. The study was conducted within a single, well-supported integrated control program, and its participants were drawn from patients already in contact with care, so the perspectives of those who dropped out entirely may be underrepresented. Qualitative findings from Kitgum and Oyam, a region still recovering from decades of conflict, may not transfer unchanged to other settings. Yet the analytical frameworks the team used are designed to support generalization of principles rather than of specific details, and the multilevel structure of the findings, individual, interpersonal and systemic, maps cleanly onto the challenges faced by RHD programs across sub-Saharan Africa and beyond. As Uganda and its neighbors scale up decentralized rheumatic heart disease services, the lesson from this study is clear and quietly radical: the monthly penicillin injection is only the visible tip of a care system, and it is the invisible architecture of trust, family, community and reliable supply that determines whether that needle is there when the patient arrives.

Subject of Research: Patient retention in secondary prophylaxis care for rheumatic heart disease in northern Uganda

Article Title: Understanding what retains patients in rheumatic heart disease care: a qualitative study of an integrated control program in northern Uganda

Article References: Pulle, J., Otim, I. O., Pardo, M., Nakagaayi, D., Sewankambo, N. K., Okello, E., Webel, A. R., Rwebembera, J., Beaton, A., Watkins, D., Danforth, K., & Kayima, J. (2026). Understanding what retains patients in rheumatic heart disease care: a qualitative study of an integrated control program in northern Uganda. BMC Public Health. https://doi.org/10.1186/s12889-026-29741-8

Image Credits: AI Generated

DOI: 10.1186/s12889-026-29741-8

Keywords: rheumatic heart disease, secondary prophylaxis, benzathine penicillin, patient retention, Uganda, ADUNU program, qualitative research, implementation science, health systems, stigma, community health workers, decentralized care